Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease

Mori MA., Ludwig RG., Garcia-Martin R., Brandão BB., Kahn CR.

Narrative Review on Neuroinflammation, published in Cell Metab (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cell Metab (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31447320
PMCID
PMC6774861
DOI
10.1016/j.cmet.2019.07.011
Citations
762

Abstract (original English)

miRNAs can be found in serum and other body fluids and serve as biomarkers for disease. More importantly, secreted miRNAs, especially those in extracellular vesicles (EVs) such as exosomes, may mediate paracrine and endocrine communication between different tissues and thus modulate gene expression and the function of distal cells. When impaired, these processes can lead to tissue dysfunction, aging, and disease. Adipose tissue is an especially important contributor to the pool of circulating exosomal miRNAs. As a result, alterations in adipose tissue mass or function, which occur in many metabolic conditions, can lead to changes in circulating miRNAs, which then function systemically. Here we review the findings that led to these conclusions and discuss how this sets the stage for new lines of investigation in which extracellular miRNAs are recognized as important mediators of intercellular communication and potential candidates for therapy of disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueCell LineAnimalsHumansMiceRatsNeurodegenerative DiseasesMetabolic DiseasesMicroRNAsCell Communication

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research